Fresenius Medical Care AG & Co. KGaA (ETR:FME) has been given a €107.00 ($124.42) target price by Deutsche Bank in a research note issued on Thursday. The brokerage currently has a “buy” rating on the stock. Deutsche Bank’s price target points to a potential upside of 52.64% from the company’s previous close.

Several other research firms have also commented on FME. Cfra set a €78.00 ($90.70) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research report on Wednesday. Credit Suisse Group set a €75.00 ($87.21) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research report on Wednesday. Independent Research set a €80.00 ($93.02) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research report on Wednesday. UBS Group set a €86.00 ($100.00) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research report on Wednesday. Finally, Barclays set a €87.20 ($101.40) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research report on Wednesday. Nine equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Fresenius Medical Care AG & Co. KGaA has an average rating of “Buy” and an average target price of €92.77 ($107.87).

Get Fresenius Medical Care AG & Co. KGaA alerts:

Shares of FME opened at €70.10 ($81.51) on Thursday. Fresenius Medical Care AG & Co. KGaA has a twelve month low of €75.53 ($87.83) and a twelve month high of €93.82 ($109.09).

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.